Sana Klinikum Offenbach

Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto—GBG 84): A randomised phase III trial (2019) Schneeweiss A, Moebus V, Tesch H, Hanusch C, Denkert C, Luebbe K, Huober J, et al. Journal article Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC) (2018) Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, et al. Conference contribution Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study (2018) Pohl E, Schneeweiss A, Hauke J, Moebus V, Furlanetto J, Denkert C, Fasching P, et al. Conference contribution Hospital Volume, In-Hospital Mortality, and Failure to Rescue in Esophageal Surgery (2018) Nimptsch U, Haist T, Krautz C, Grützmann R, Mansky T, Lorenz D Journal article Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials (2018) Van Mackelenbergh MT, Denkert C, Nekljudova V, Karn T, Schem C, Marme F, Stickeler E, et al. Journal article Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44) (2018) Untch M, Von Minckwitz G, Gerber B, Schem C, Rezai M, Fasching P, Tesch H, et al. Journal article Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto (2018) Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, Fasching P, Lederer B, et al. Journal article QOL After APBI (Multicatheter Brachytherapy) Versus WBI: 5-Year Results, Phase 3 GEC-ESTRO Trial (2018) Schaefer R, Strnad V, Polgar C, Uter W, Hildebrandt G, Ott OJ, Kauer-Dorner D, et al. Conference contribution Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) - Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities (2018) Emons G, Steiner E, Vordermark D, Uleer C, Bock N, Paradies K, Ortmann O, et al. Journal article Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) - Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer (2018) Emons G, Steiner E, Vordermark D, Uleer C, Bock N, Paradiess K, Ortmann O, et al. Journal article